Cannabinoid-based biopharmaceutical company InMed Pharmaceuticals (TSX: IN) (OTCQX: IMLFF) today announced its addition of Dr. Steven M. Dinh to its Scientific Advisory Board. Per the update, Dr. Dinh brings more than 30 years of pharmaceutical and biotech executive leadership, as well as proven success in developing and commercializing dermal pharmaceutical products by applying innovative drug delivery technologies. Over 22 issued U.S. patents, 44 published patent applications, 6 NDA approvals and the successful commercialization of 9 products to serve the unmet needs of patients are a result of Dr. Dinh’s accomplishments and innovations in pharmaceutical product development and drug delivery technology.
“As we approach human trials with INM-750 for the treatment of Epidermolysis Bullosa (“EB”), Dr. Dinh’s experience in the development of dermatology-focused therapeutics, with a true expertise in drug delivery, will be a highly value-added skill set for InMed,” Eric A. Adams, president and CEO of InMed stated in the news release. “He will be instrumental in helping our scientific staff transition the program from pre-clinical development to being on the doorstep of our first human trials.”
To view the full press release, visit http://nnw.fm/DlO9k
About InMed Pharmaceuticals
InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the company. For more information, visit the company’s website at www.InMedPharma.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive instant SMS alerts, text STOCKS to 77948
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com